Literature DB >> 1339322

Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material.

J S Crowe1, V S Hall, M A Smith, H J Cooper, J P Tite.   

Abstract

Expression of CAMPATH-1H, a humanized MoAb directed against an abundant surface antigen on human lymphocytes, has been studied using transfected myeloma cells. As the site of chromosome integration of DNA transfected into a cell is random we investigated the feasibility and frequency of hitting a 'jackpot' site for expression after co-transfection with CAMPATH-1H heavy and light chain constructs in genomic context. A cell line generating 40 micrograms/ml of CAMPATH-1H in spent culture supernatant was achieved. The full nucleotide sequence of the CAMPATH-1H heavy and light chain cDNA clones is also shown, in addition a comparison of the effector mechanisms, antibody dependent cellular cytotoxicity and complement dependent cytotoxicity, of myeloma cell and Chinese hamster ovary (CHO) cell-derived CAMPATH-1H is reported.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1339322      PMCID: PMC1554244          DOI: 10.1111/j.1365-2249.1992.tb06421.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.

Authors:  G Hale; M J Dyer; M R Clark; J M Phillips; R Marcus; L Riechmann; G Winter; H Waldmann
Journal:  Lancet       Date:  1988-12-17       Impact factor: 79.321

Review 2.  Glycobiology.

Authors:  T W Rademacher; R B Parekh; R A Dwek
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

Review 3.  Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases.

Authors:  M J Van Kroonenburgh; E K Pauwels
Journal:  Nucl Med Commun       Date:  1988-11       Impact factor: 1.690

4.  Isolation of low-frequency class-switch variants from rat hybrid myelomas.

Authors:  G Hale; S P Cobbold; H Waldmann; G Easter; P Matejtschuk; R R Coombs
Journal:  J Immunol Methods       Date:  1987-10-23       Impact factor: 2.303

5.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

6.  A hapten-specific chimaeric IgE antibody with human physiological effector function.

Authors:  M S Neuberger; G T Williams; E B Mitchell; S S Jouhal; J G Flanagan; T H Rabbitts
Journal:  Nature       Date:  1985 Mar 21-27       Impact factor: 49.962

7.  A new human B-cell non-Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations.

Authors:  M J Dyer; P Fischer; E Nacheva; W Labastide; A Karpas
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

8.  Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.

Authors:  R W Schroff; K A Foon; S M Beatty; R K Oldham; A C Morgan
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

9.  Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG.

Authors:  N Tsuchiya; T Endo; K Matsuta; S Yoshinoya; T Aikawa; E Kosuge; F Takeuchi; T Miyamoto; A Kobata
Journal:  J Rheumatol       Date:  1989-03       Impact factor: 4.666

10.  Reshaping human antibodies for therapy.

Authors:  L Riechmann; M Clark; H Waldmann; G Winter
Journal:  Nature       Date:  1988-03-24       Impact factor: 49.962

View more
  21 in total

1.  Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.

Authors:  Amer Awad; Olaf Stüve
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

Review 2.  Monoclonal antibodies in treatment of multiple sclerosis.

Authors:  P S Rommer; A Dudesek; O Stüve; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

3.  FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.

Authors:  Nada S Alakhras; Jiabin Qiu; Guilherme V Rocha; Derrick R Witcher; Anja Koester; Jinsam You; David A Schaer; Rikke B Holmgaard; Kyla Driscoll; Jeffrey A Willy; Laurent P Malherbe
Journal:  MAbs       Date:  2018-07-26       Impact factor: 5.857

4.  The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation.

Authors:  M K Spriggs; R J Armitage; M R Comeau; L Strockbine; T Farrah; B Macduff; D Ulrich; M R Alderson; J Müllberg; J I Cohen
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

Review 5.  The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.

Authors:  Samantha M Jaglowski; Lapo Alinari; Rosa Lapalombella; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

6.  Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells.

Authors:  Jia-xi Song; Wang-li Cao; Fang-qiu Li; Li-ning Shi; Xuan Jia
Journal:  Med Oncol       Date:  2011-12-24       Impact factor: 3.064

7.  Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.

Authors:  W Rowan; J Tite; P Topley; S J Brett
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

8.  Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.

Authors:  Mark S Freedman; Johanne M Kaplan; Silva Markovic-Plese
Journal:  J Clin Cell Immunol       Date:  2013-07-08

Review 9.  Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.

Authors:  P S Rommer; U K Zettl; B Kieseier; H-P Hartung; T Menge; E Frohman; B M Greenberg; B Hemmer; O Stüve
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

10.  Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.

Authors:  Akito Natsume; Rinpei Niwa; Mitsuo Satoh
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.